Free Trial
NYSE:RMD

ResMed (RMD) Stock Price, News & Analysis

$210.35
-1.38 (-0.65%)
(As of 06/17/2024 ET)
Today's Range
$205.38
$211.69
50-Day Range
$173.86
$220.63
52-Week Range
$132.24
$229.97
Volume
1.02 million shs
Average Volume
1.01 million shs
Market Capitalization
$30.90 billion
P/E Ratio
32.31
Dividend Yield
0.91%
Price Target
$202.80

ResMed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
3.6% Downside
$202.80 Price Target
Short Interest
Bearish
6.72% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.85mentions of ResMed in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$6.67 M Sold Last Quarter
Proj. Earnings Growth
13.25%
From $7.70 to $8.72 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.51 out of 5 stars

Medical Sector

71st out of 913 stocks

Surgical & Medical Instruments Industry

10th out of 99 stocks

RMD stock logo

About ResMed Stock (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock Price History

RMD Stock News Headlines

(RMD) - Analyzing ResMed's Short Interest
ResMed Inc. (RMD) Q3 2024 Earnings Call Transcript
Why ResMed Stock Is Soaring Today
Australian Stocks: ResMed (RMD) Shares Surge on Robust Q3 Results
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/25/2024
Ex-Dividend for 6/13 Dividend
5/08/2024
Dividend Payable
6/13/2024
Today
6/17/2024
Fiscal Year End
6/30/2024
Next Earnings (Estimated)
8/01/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
76115210
Employees
10,140
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$202.80
High Stock Price Target
$238.00
Low Stock Price Target
$165.00
Potential Upside/Downside
-3.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$897.56 million
Pretax Margin
25.83%

Debt

Sales & Book Value

Annual Sales
$4.22 billion
Cash Flow
$7.76 per share
Book Value
$28.11 per share

Miscellaneous

Free Float
145,129,000
Market Cap
$30.90 billion
Optionable
Optionable
Beta
0.69

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Should I Buy ResMed Stock? RMD Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • ResMed Inc. reported a strong quarterly earnings result, beating the consensus estimate by $0.22 per share, indicating solid financial performance.
  • The company has a healthy quick ratio of 1.97 and a current ratio of 3.04, reflecting strong liquidity positions to meet short-term obligations.
  • Institutional investors, including Norges Bank and Morgan Stanley, have been increasing their stakes in ResMed, signaling confidence in the company's future growth prospects.
  • The company's stock price has been performing well, with insiders selling shares at an average price of $173.25, indicating positive market sentiment.
  • ResMed announced a quarterly dividend with a yield of 0.88%, providing investors with a steady income stream.

Cons

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • Corporate insiders have been selling shares of ResMed in the last 90 days, raising concerns about insider sentiment towards the company.
  • The debt-to-equity ratio of ResMed is 0.22, indicating a moderate level of leverage that investors should consider in their risk assessment.
  • While the company has shown growth in revenue, investors should monitor if this growth is sustainable over the long term.
  • ResMed's dividend payout ratio is 29.49%, which may limit the company's ability to reinvest in growth opportunities.
  • Investors should be cautious about the overall market conditions and potential regulatory changes that could impact the healthcare sector, where ResMed operates.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 1, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

RMD Stock Analysis - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price target for 2024?

10 Wall Street research analysts have issued twelve-month target prices for ResMed's stock. Their RMD share price targets range from $165.00 to $238.00. On average, they expect the company's stock price to reach $202.80 in the next twelve months. This suggests that the stock has a possible downside of 3.6%.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2024?

ResMed's stock was trading at $172.02 at the start of the year. Since then, RMD stock has increased by 22.3% and is now trading at $210.35.
View the best growth stocks for 2024 here
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our RMD earnings forecast
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its earnings results on Thursday, April, 25th. The medical equipment provider reported $2.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.22. The medical equipment provider had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.17 billion. ResMed had a net margin of 20.91% and a trailing twelve-month return on equity of 24.43%. The business's revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business earned $1.68 earnings per share.
Read the conference call transcript
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, April 25th. Shareholders of record on Thursday, May 9th will be paid a dividend of $0.48 per share on Thursday, June 13th. This represents a $1.92 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Wednesday, May 8th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 0.91%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 29.49%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 22.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's major shareholders?

ResMed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (12.10%), Bank of New York Mellon Corp (2.59%), Congress Asset Management Co. MA (0.40%), Los Angeles Capital Management LLC (0.34%), Tandem Investment Advisors Inc. (0.33%) and Swiss National Bank (0.30%). Insiders that own company stock include Brett Sandercock, Carol Burt, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Witte Jan De.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
This page (NYSE:RMD) was last updated on 6/18/2024 by MarketBeat.com Staff

From Our Partners